Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma announced a 29% year-over-year revenue increase to $44.5 million for the first half of 2026, driven by product sales growth. The company expanded executive leadership to strengthen commercial capabilities and continues progressing nine registrational Phase III global clinical trials, including FDA and EMA-cleared studies of its onc…